Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I-II Study of MEK 162 for Children With Low-Grade Gliomas and Other Ras/Raf/ERK Pathway Activated Tumors

NCT02285439 is registered in ClinicalTrials.gov with Children's Hospital Los Angeles as lead sponsor.

NCT NCT02285439
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02285439 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I-II Study of MEK 162 for Children With Low-Grade Gliomas and Other Ras/Raf/ERK Pathway Activated Tumors
Lead sponsor
Children's Hospital Los Angeles
Phase
Phase 1/2
Overall status
Completed
Start date
May 4, 2016
Completion date
August 1, 2025
Enrollment
105 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

low-grade gliomas, malignant neoplasms, brain, soft tissue neoplasms